Glythera Limited, the next generation Antibody Drug Conjugate development Company, and IONTAS Limited, a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, today announced a collaboration for the development of ADCs for difficult-to-treat cancers.
Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting (WB), immunoprecipitation (IP), flow cytometry, enzyme-linked immunosorbent assays (ELISA), quantitative immunofluorescence (QIF) and immunohistochemistry (IHC).
It has been 16 years since the first monoclonal antibody was approved for therapy in acute transplant rejection. Now, with a further nine therapeutic monoclonal antibodies approved for use and some 16 in phase III trials or beyond, are we still grappling with the same old issues or are magic bullets finally hitting the mark?
Monoclonal antibodies are the fastest-growing category of research within the biotech and pharmaceutical industries. Several monoclonal antibodies are listed in the top 10 selling blockbusters, and the market forecast predicts that the number of monoclonal antibodies within the top 10 will further increase1.